Efficacy and safety of perrectal 400 microgram misoprostol versus intravenous 200 microgram methylergometrine in the management of third stage of labor for prevention of postpartum haemorrhage: A randomized control trial

Anubhuti Jain; Mahendra Kumar Jain; Parul Jain; Ashish Kumar Jain

doi:10.53730/ijhs.v6nS5.11862

Authors

Anubhuti Jain Assistant Professor in the department of obstetrics and Gynaecology Geetanjali medical college and hospital Udaipur, Rajasthan
Mahendra Kumar Jain
drmahendra78@gmail.com
Associate professor in department of neonatology, AIIMS bhopal m.p.
Parul Jain Assistant professor, Dept of Periodontology, Government College of Dentistry Indore
Ashish Kumar Jain Professor, Dept of cardiology, MGM medical College and hospital Indore

Keywords:

postpartum haemorrhage, childbirth, third stage labor

Abstract

Background: Objective: Postpartum haemorrhage (PPH) is a major cause of mortality and morbidity during childbirth, especially in developing countries. Misoprostol is a cheap, safe, widely available, and stable at room temperature, does not required any intravenous accesses and having few mild side effects. In resource-poor countries with limited facilities, misoprostol may be one of the important interventions to prevent PPH. We aimed to assess the effectiveness of perrectal low dose misoprostol for the prevention of PPH. Method: We designed a prospective randomized control trial, single centre study. 138 indoor low risk pregnant women with gestational age at least 37 weeks who anticipated vaginal delivery were randomly assigned to perrectal 400 microgram misoprostol (n = 71) or intravenous 200 microgram (n = 67) methylergometrine after delivery of baby and placenta. The primary outcome was incidence of PPH (estimated blood loss >500 ml after delivery of baby and placenta). Results: In this study out of 138 low risk pregnancy, no women developed PPH, no patient required additional dose of oxytocin, no patient required any form of transfusion.

Downloads

Download data is not yet available.

References

A. Aronsson, M. Bygdeman and K. Gemzell-Danielsson, Effects of misoprostol on uterine contractility following different routes of administration, Hum Reprod 19 (2004), pp. 81–84.

Amant F,Spitz B, Timmerman D, et al. Misoprostol compared with methylergometrine for the Prevention of postpartum haemorrhage:a double blind randomized trial. Br J Obstet Gynaecol. 1999;106:1066–1070.

Bradley S, Prata N, Young Lin N, et al. Cost effectiveness of misoprostol to control postpartum Hemorrhage in low resource settings. Int J Gynecol and Obstet. 2007;97:52–56.

Callister, L. C., and Edwards, J. E. Sustainable Development Goals and the Ongoing Process of Reducing Maternal Mortality JOGNN, 46, e56–e64; 2017. http://dx.doi.org/ n10.1016/ j.jogn.2016.10.009.

Derman RJ, Kodkany BS, Goudar SS, et al. Oral misoprostol in preventing postpartum haemorrhage In resource poor communities:a randomized controlled trial. Lancet.2006;368:1248–1253.

Gaud HT, Connors KA. Misoprostol dehydration kinetics in aqueous solution in the presence of hydroxypropylmethylcellulose. J Pharm Sci 1992; 81: 145-8.

H. El-Refaey, D. Rajasekar, M. Abdalla, L. Calder and A. Templeton, Induction of abortion with

International Confederation of Mid-wives and International Federation of Gynaecologists and Obstetricians (FIGO).Joint Statement: management of the third Stage of labour to prevent postpartum haemorrhage. Maternal and Child Health.2004;49:76–77.

K. Gemzell-Danielsson, L. Marions, A. Rodriguez, B.W. Spur, P.Y.K. Wong and M. Bygdeman, comparison between oral and vaginal administration of misoprostol on uterine contractility, Obstet Gynaecol 93 (1999), pp. 275–280.

Kararli T, Catalano T, Needham TE, et al. Mechanism of misoprostol stabilization in hydroxylpropyl methylcellulose. Adv Exp Med Biol 1991;302: 275-89.

Khan KS, Wojdyla D, Say L, Gu¨ lmezoglu AM, Van Look PFA. WHO analysis of causes of maternal death: a systematic review. Lancet2006;367:1066–74.

Mbonye A, Asimwe, Kabarangira, et al. Emergency obstetric care as the priority intervention to reduce maternal mortality in Uganda. Int J Gynaecol Obstet. 2007;96:220–225.

mifepristone (RU 486) and oral or vaginal misoprostol, N Eng J Med 332 (1995), pp. 983–987.

Nasr A, Shahin A, Elsamman A, et al. Rectal misoprostol versus intravenous oxytocin for Prevention of postpartum hemorrhage. Int J Gynaecol Obstet. 2009;105:244–247.

O’Brien P, El-Refaey H. The management of the third stage of labor using misoprostol in low risk women. Contemp Rev Obstet Gynecol 1997; 9(1): 27-32.

oralmisoprostol in termination of second trimester pregnancy, Obstet Gynecol 90 (1997),

P.C.Ho,S.W.Ngai,K.L.Liu,G.C.Wong and S.W.Lee, Vaginal misoprostol compared with

Panel reviewer #1 comment, 5/2000. -8.

Panel reviewer #5 comment, 5/2000.

Parsons S,Walley R,Crane J,et al.Rectal misoprostol versus oxytocin in the management of the

pp.735-738.Abstract| View Record in Scopus | Cited By in Scopus (153).

Surbek DV, Fehr PM, Hosli I, et al. Oral misoprostol for third stage of labor: a randomized placebo controlled trial. Obstet Gynecol 1999; 94(2): 255.

Third stage of labour. J Obstet Gynaecol Can 2007;29:711–718.

University of California, IrvineLindmark G, Nystrom L (Maternal Mortality Study Group).A community based investigationof causes of maternal mortality in rural and urban Zimbabwe. Central African Journal of Medicine 1997;41:105{13

VimalaN,Mittal S,Kumar S, et al.Sublingual misoprostol versus methylergometrine for active Management of the third stage of labor. Int J Gynaecol Obstet. 2004;87:1–5.

WHO, UNICEF, UNFPA. The World Bank. Maternal mortality in 2005: estimates developed by WHO, UNICEF, UNFPA, and the World Bank. In: World Health Organization, editor. WHO Press, World Health Organization. Geneva: World Health Organization;2005. pp. 16–17, 23–27, 29–38.

World Health Organization.The prevention and management of postpartum haemorrhage. WHO Report of Technical Working Group. Geneva: World Health Organization, 1990.